Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(11%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
4
44%
Ph phase_1
2
22%
Ph phase_2
2
22%

Phase Distribution

2

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(1)
Other(7)

Detailed Status

unknown7
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 22 (25.0%)
Phase 34 (50.0%)

Trials by Status

unknown778%
recruiting111%
completed111%

Recent Activity

1 active trials
Showing 5 of 9
recruiting

COVID-19 Vaccines Safety Tracking (CoVaST)

NCT04834869
unknownphase_1

Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray

NCT05248373
unknownphase_2

Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

NCT04640233
unknownphase_2

The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older

NCT04587219
unknownphase_3

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19

NCT04530396
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04834869

COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting
NCT05248373Phase 1

Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray

Unknown
NCT04640233Phase 2

Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

Unknown
NCT04587219Phase 2

The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older

Unknown
NCT04530396Phase 3

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19

Unknown
NCT04656613Phase 3

A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE

Unknown
NCT04564716Phase 3

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus

Unknown
NCT04642339Phase 3

Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela

Unknown
NCT04436471Phase 1

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9